醫療使用

副作用

• 鎮靜和困倦（通常是短暫的）Sedation and sleepiness (often transient)
• 頭暈 Dizziness
• 協調不佳 Disturbed coordination
• 混亂 Confusion
• 躁動不安 Restlessness
• 兴奋 Excitation
• 緊張 Nervousness
• 震顫 Tremor
• 易怒 Irritability
• 失眠 Insomnia
• 感覺異常 Paresthesias
• 神經炎 Neuritis
• 抽搐 Convulsions
• 欣快感 Euphoria
• 幻覺 Hallucinations
• 歇斯底里 Hysteria
• 模糊 Faintness
• 皮疹和水腫的過敏表現 Allergic manifestation of rash and edema
• 發汗 Diaphoresis
• 蕁麻疹 Urticaria
• 對光敏感 Photosensitivity
• 急性迷路炎 Acute labyrinthitis
• 複視（雙眼） Diplopia (seeing double)
• 眩暈 Vertigo
• 耳鳴 Tinnitus
• 低血壓 Hypotension (low blood pressure)
• 心悸 Palpitation
• 期前收缩 Extrasystoles
• 過敏性休克 Anaphylactic shock
• 溶血性貧血 Hemolytic anemia
• 諸如白细胞减少症，粒細胞缺乏症和血小板減少症等血液異常 Blood dyscrasias such asleukopenia,agranulocytosis andthrombocytopenia
• 膽汁淤積 Cholestasis
• 對肝臟的影響：
  • 肝炎 Hepatitis
  • 黄疸 Jaundice
  • 肝功能衰竭 Hepatic failure^[19]
  • 肝功能異常 Hepatic function abnormality
• 上腹窘迫 Epigastric distress
• 食欲不振 Anorexia
• 噁心 Nausea
• 嘔吐 Vomiting
• 腹瀉 Diarrhea
• 抗胆碱能副作用:
  • 視力模糊 Blurred vision
  • 便秘 Constipation
  • 口腔乾燥症（口乾） Xerostomia (dry mouth)
  • 心動過速（高心率）Tachycardia (high heart rate)
  • 尿瀦留 Urinary retention
  • 排尿困难 Difficulty passing urine
  • 鼻塞 Nasal congestion
  • 鼻或喉嚨乾燥 Nasal or throat dryness
• 頻尿 Urinary frequency
• 早期月經 Early menses
• 支氣管分泌物增厚 Thickening of bronchial secretions
• 胸悶氣喘 Tightness of chest and wheezing
• 疲勞 Fatigue
• 寒意 Chills
• 頭痛 Headache
• 食慾增加 Increased appetite
• 體重增加 Weight gain

用藥過量

藥理

藥效學

藥物代謝動力學

化學

研究

獸醫用途

參考資料

1. ^Cyproheptadine.Dictionary.com Unabridged.蘭登書屋. 
2. ^^2.02.1Gunja N, Collins M, Graudins A. A comparison of the pharmacokinetics of oral and sublingual cyproheptadine. Journal of Toxicology. Clinical Toxicology. 2004,42 (1): 79–83.PMID 15083941.S2CID 20196551.doi:10.1081/clt-120028749. 
3. ^^3.03.13.23.3CYPROHEPTADINE HYDROCHLORIDE tablet [Boscogen, Inc.]. DailyMed. Boscogen, Inc. November 2010 [26 October 2013]. （原始内容(PDF)存档于2013-07-04）. 
4. ^^4.04.14.24.3PRODUCT INFORMATION PERIACTIN® (cyproheptadine hydrochloride)(PDF). Aspen Pharmacare Australia. Aspen Pharmacare Australia Pty Ltd. 17 November 2011 [26 October 2013]. （原始内容(PDF)存档于29 October 2013）. 
5. ^Fischer, Jnos; Ganellin, C. Robin.Analogue-based Drug Discovery. John Wiley & Sons. 2006: 547 [2020-12-15].ISBN 9783527607495. （原始内容存档于2021-08-29）（英语）. 
6. ^MedlinePlus Drug Information: Cyproheptadine. [2020-12-15]. （原始内容存档于2008-10-01）. 
7. ^^7.07.1De Bruyne, P; Christiaens, T; Boussery, K; Mehuys, E; Van Winckel, M. Are antihistamines effective in children? A review of the evidence. Archives of Disease in Childhood. January 2017,102 (1): 56–60.PMID 27335428.S2CID 21185048.doi:10.1136/archdischild-2015-310416. 
8. ^Saito, Y; Yamanaka, G; Shimomura, H; Shiraishi, K; Nakazawa, T; Kato, F; Shimizu-Motohashi, Y; Sasaki, M; Maegaki, Y. Reconsideration of the diagnosis and treatment of childhood migraine: A practical review of clinical experiences. Brain & Development. May 2017,39 (5): 386–394.PMID 27993427.S2CID 34703034.doi:10.1016/j.braindev.2016.11.011. 
9. ^Salvatore, S; Barberi, S; Borrelli, O; Castellazzi, A; Di Mauro, D; Di Mauro, G; Doria, M; Francavilla, R; Landi, M; Martelli, A; Miniello, VL; Simeone, G; Verduci, E; Verga, C; Zanetti, MA; Staiano, A; SIPPS Working Group on, FGIDs.Pharmacological interventions on early functional gastrointestinal disorders. Italian Journal of Pediatrics. 16 July 2016,42 (1): 68.PMC 4947301 .PMID 27423188.doi:10.1186/s13052-016-0272-5. 
10. ^Taylor, David; Paton, Carol; Kapur, Shitij.The Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons. 2015: 85 [2020-12-15].ISBN 9781118754573. （原始内容存档于2021-08-28）（英语）. 
11. ^Szepietowski, JC; Reszke, R. Psychogenic Itch Management50. 2016: 124–32.ISBN 978-3-318-05888-8.PMID 27578081.doi:10.1159/000446055. |journal=被忽略 (帮助)
12. ^Ashton AK, Weinstein WL.Cyproheptadine for drug-induced sweating.American Journal of Psychiatry. May 2002,159 (5): 874–5 [2020-12-15].PMID 11986151.doi:10.1176/appi.ajp.159.5.874-a. （原始内容存档于2012-03-19）. 
13. ^Pfendner, Ellen G.; Bruckner, Anna L.Epidermolysis Bullosa Simplex. GeneReviews. October 13, 2016 [2020-12-15].PMID 20301543. （原始内容存档于2020-10-22）. 
14. ^Ciproheptadina, estimulante del apetito (Cyproheptadine, appetite stimulant). [2020-12-15]. （原始内容存档于2020-10-24）. 
15. ^Bioplex NF. [2020-12-15]. （原始内容存档于2018-04-18）. 
16. ^Harrison ME, Norris ML, Robinson A, Spettigue W, Morrissey M, Isserlin L. Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review.. Appetite. 2019,137: 62–72.PMID 30825493.S2CID 72333631.doi:10.1016/j.appet.2019.02.012. 
17. ^Rossi, S (编). Australian Medicines Handbook 2013. Adelaide: The Australian Medicines Handbook Unit Trust. 2013.ISBN 978-0-9805790-9-3. 
18. ^Iqbal, MM; Basil, MJ; Kaplan, J; Iqbal, MT. Overview of serotonin syndrome. Annals of Clinical Psychiatry. November 2012,24 (4): 310–8.PMID 23145389. 
19. ^Chertoff, Jason.Cyproheptadine-Induced Acute Liver Failure. ACG Case Reports Journal. 8 July 2014,1 (4): 212–213.PMC 4286888 .PMID 25580444.doi:10.14309/crj.2014.56. 
20. ^^20.020.1Roth, BL; Driscol, J.PDSP K_i Database. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. [14 August 2017]. （原始内容存档于2021-08-28）. 
21. ^Pucci E, Petraglia F. Treatment of androgen excess in females: yesterday, today and tomorrow. Gynecol. Endocrinol. December 1997,11 (6): 411–33.PMID 9476091.doi:10.3109/09513599709152569. 
22. ^Lindsay Murray; Frank Daly; David McCoubrie; Mike Cadogan.Toxicology Handbook. Elsevier Australia. 15 January 2011: 388 [27 November 2011].ISBN 978-0-7295-3939-5. （原始内容存档于2014-01-01）. 
23. ^Buoli, M; Altamura, AC. May non-antipsychotic drugs improve cognition of schizophrenia patients?. Pharmacopsychiatry. March 2015,48 (2): 41–50.PMID 25584772.doi:10.1055/s-0034-1396801. 
24. ^^24.024.1Dabaghzadeh, F; Khalili, H; Ghaeli, P; Dashti-Khavidaki, S. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz. Expert Opinion on Pharmacotherapy. December 2012,13 (18): 2613–24.PMID 23140169.S2CID 25769557.doi:10.1517/14656566.2012.742887. 
25. ^Nunes, LV; Moreira, HC; Razzouk, D; Nunes, SO; Mari Jde, J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. Journal of Sex & Marital Therapy. 2012,38 (3): 281–301.PMID 22533871.S2CID 23406005.doi:10.1080/0092623X.2011.606883. 
26. ^Agnew, W; Korman, R. Pharmacological appetite stimulation: rational choices in the inappetent cat. Journal of Feline Medicine and Surgery. September 2014,16 (9): 749–56.PMID 25146662.S2CID 37126352.doi:10.1177/1098612X14545273. 
27. ^^27.027.1Dowling PM.Systemic Therapy of Airway Disease: Cyproheptadine. Kahn CM, Line S, Aiello SE (编). The Merck Veterinary Manual 9th.John Wiley & Sons. February 8, 2005 [2022-06-16].ISBN 978-0-911910-50-6. （原始内容存档于2016-03-04）.  Retrieved on October 26, 2008.
28. ^Dowling PM.Drugs Affecting Appetite. Kahn CM, Line S, Aiello SE (编).The Merck Veterinary Manual 9th.John Wiley & Sons. February 8, 2005 [2022-06-16].ISBN 978-0-911910-50-6. （原始内容存档于2012-10-28）.  Retrieved on October 26, 2008.
29. ^Durham, AE. Therapeutics for Equine Endocrine Disorders. The Veterinary Clinics of North America. Equine Practice. April 2017,33 (1): 127–139.PMID 28190613.doi:10.1016/j.cveq.2016.11.003. 
30. ^Merck Vet Manual.Hirsutism Associated with Adenomas of the Pars Intermedia. [April 24, 2011]. （原始内容存档于2016-03-03）.